Institutional Investors Lead Shift in Intercept Inc (NASDAQ:ICPT) Sentiment

May 17, 2018 - By David Engel

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Sentiment for Intercept Inc (NASDAQ:ICPT)

Intercept Inc (NASDAQ:ICPT) institutional sentiment decreased to 1.31 in 2017 Q4. Its down -0.02, from 1.33 in 2017Q3. The ratio has worsened, as 80 institutional investors started new and increased positions, while 61 sold and decreased positions in Intercept Inc. The institutional investors in our partner’s database now own: 17.97 million shares, down from 18.23 million shares in 2017Q3. Also, the number of institutional investors holding Intercept Inc in their top 10 positions increased from 0 to 1 for an increase of 1. Sold All: 19 Reduced: 42 Increased: 44 New Position: 36.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $1.81 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

The stock increased 0.13% or $0.09 during the last trading session, reaching $71.47. About 150,474 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since May 17, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on July, 30. They expect $-3.06 earnings per share, up 11.56 % or $0.40 from last year’s $-3.46 per share. After $-3.22 actual earnings per share reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.97 % EPS growth.

Sarissa Capital Management Lp holds 2.73% of its portfolio in Intercept Pharmaceuticals, Inc. for 182,300 shares. Bb Biotech Ag owns 485,719 shares or 0.8% of their US portfolio. Moreover, Altrinsic Global Advisors Llc has 0.7% invested in the company for 310,300 shares. The New York-based Spark Investment Management Llc has invested 0.57% in the stock. Regal Investment Advisors Llc, a Michigan-based fund reported 30,147 shares.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Ratings analysis reveals 67% of Intercept Pharmaceuticals’s analysts are positive. Out of 6 Wall Street analysts rating Intercept Pharmaceuticals, 4 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $45.0 while the high is $253.0. The stock’s average target of $122.17 is 70.94% above today’s ($71.47) share price. ICPT was included in 10 notes of analysts from December 13, 2017. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Buy” rating given on Monday, January 22 by Credit Suisse. The company was maintained on Thursday, February 1 by Wedbush. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Buy” rating by Wedbush on Thursday, January 25. As per Monday, February 12, the company rating was maintained by Wedbush. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, February 15. The firm has “Hold” rating given on Tuesday, February 13 by Wells Fargo. Goldman Sachs downgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Wednesday, February 7 to “Sell” rating. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Tuesday, April 17 with “Outperform” rating.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Streetinsider.com which released: “Intercept Pharma (ICPT) Tops Q1 EPS by 20c” on May 08, 2018, also Nasdaq.com with their article: “Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance …” published on May 08, 2018, Seekingalpha.com published: “Intercept Pharmaceuticals (ICPT) Q1 2018 Results – Earnings Call Transcript” on May 08, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Nasdaq.com and their article: “Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors” published on April 24, 2018 as well as Seekingalpha.com‘s news article titled: “Intercept: Still Not ‘Intercepting’ At These Levels” with publication date: May 16, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.